The MIF rs755622 Variant may Increase Susceptibility of Breast Cancer but not Gastrointestinal Cancer in a Turkish Population

pehlivan, sacide; Gunaldi, Meral; PEHLİVAN, MUSTAFA; Oyacı, Yasemin; Isiksacan, Nilgun; Nursal, Ayse Feyda

doi:10.5505/tjo.2020.2186

The MIF rs755622 Variant may Increase Susceptibility of Breast Cancer but not Gastrointestinal Cancer in a Turkish Population

Sacide PEHLİVAN, (İstanbul Üniversitesi, İstanbul Tıp Fakültesi, Tıbbi Biyoloji Anabilim Dalı, İstanbul, Türkiye)

Nilgün IŞIKSAÇAN, (Dr.Sadi Konuk Eğitim ve Araştırma Hastanesi, İmmünoloji Kliniği, İstanbul, Türkiye)

Mustafa PEHLİVAN, (Gaziantep Üniversitesi, Tıp Fakültesi, Hematoloji Anabilim Dalı, Gaziantep, Türkiye)

Meral GÜNALDI, (Dr. Sadi Konuk Eğitim ve Araştırma Hastanesi, Onkoloji Bölümü, İstanbul, Türkiye)

Yasemin OYACI, (İstanbul Üniversitesi, İstanbul Tıp Fakültesi, Tıbbi Biyoloji Anabilim Dalı, İstanbul, Türkiye)

Ayşe Feyda NURSAL (Hitit Üniversitesi, Tıp Fakültesi, Tıbbi Genetik Anabilim Dalı, Çorum, Türkiye)

Türk Onkoloji Dergisi

0 0

Yıl: 2020 Cilt: 35 Sayı: 3 Sayfa Aralığı: 283 - 288 Metin Dili: İngilizce DOI: 10.5505/tjo.2020.2186 İndeks Tarihi: 26-11-2020

The MIF rs755622 Variant may Increase Susceptibility of Breast Cancer but not Gastrointestinal Cancer in a Turkish Population

Öz:

OBJECTIVEAn increasing number of epidemiological and molecular evidence proposes that inflammation is a significantfactor in the etiology of cancers. Macrophage Migration Inhibitory Factor (MIF) encodes a lymphokineinvolved in cell-mediated immunity, immunoregulation, and inflammation. It has been reported thatMIF is linked with a higher risk of several cancer types. In the present study, we investigated the associationof MIF rs755622 variant with the risk of breast cancer (BC) and gastrointestinal cancer in a Turkish cohort.METHODSThe present study included a total of 153 subjects, which consisted of 33 BC patients, 53 gastrointestinalcancer patients and 67 healthy controls. Genomic DNA extracted from peripheral venous blood. Thers755622 variant of the MIF gene was genotyped using polymerase chain reaction-restriction fragmentlength polymorphism (PCR-RFLP) method. The results were statistically analyzed by calculating theodds ratios (OR) and 95% confidence intervals (CI) using the χ2 test.RESULTSThere was a statistical difference between the BC patients and controls for the MIF rs755622 variant.MIF rs755622 GG genotype and G allele were increased in BC patients compared to controls (p=0.016,p=0.017, respectively). No significant difference was observed between gastrointestinal cancer patientsand controls for the MIF rs755622 variant (p>0.05).CONCLUSIONOur results showed that the MIF rs755622 variant might play a potential role in BC physiopathology.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66(1):7–30.
2. Pusztai L, Karn T, Safonov A, Abu-Khalaf MM, Bianchini G. New Strategies in Breast Cancer: Immunotherapy. Clin Cancer Res 2016;22(9):2105–10.
3. Toiyama Y, Miki C, Inoue Y, Tanaka K, Mohri Y, Kusunoki M. Evaluation of an inflammation-based prognostic score for the identification of patients requiring postoperative adjuvant chemotherapy for stage II colorectal cancer. Exp Ther Med 2011;2(1):95–101.
4. Tan BH, Ross JA, Kaasa S, Skorpen F, Fearon KC; European Palliative Care Research Collaborative. Identification of possible genetic polymorphisms involved in cancer cachexia: a systematic review. J Genet 2011;90(1):165–77.
5. Kim KW, Kim HR. Macrophage migration inhibitory factor: a potential therapeutic target for rheumatoid arthritis. Korean J Intern Med 2016;31(4):634–42.
6. O’Reilly C, Doroudian M, Mawhinney L, Donnelly SC. Targeting MIF in Cancer: Therapeutic Strategies, Current Developments, and Future Opportunities. Med Res Rev 2016;36(3):440–60.
7. Yasasever V, Camlica H, Duranyildiz D, Oguz H, Tas F, Dalay N. Macrophage migration inhibitory factor in cancer. Cancer Invest 2007;25(8):715–9.
8. Donn RP, Shelley E, Ollier WE, Thomson W; British Paediatric Rheumatology Study Group. A novel 5’-flanking region polymorphism of macrophage migration inhibitory factor is associated with systemiconset juvenile idiopathic arthritis. Arthritis Rheum 2001;44(8):1782–5.
9. Lin S, Wang M, Liu X, Zhu W, Guo Y, Dai Z, et al. Association of genetic polymorphisms in MIF with breast cancer risk in Chinese women. Clin Exp Med 2017;17(3):395–401.
10. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16(3):1215.
11. Akcali A, Pehlivan S, Pehlivan M, Sever T, Neyal M. Association of macrophage migration inhibitory factor gene promoter polymorphisms with multiple sclerosis in Turkish patients. J Int Med Res 2010;38(1):69–77.
12. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013;39(1):1–10.
13. Nobre CC, de Araújo JM, Fernandes TA, Cobucci RN, Lanza DC, Andrade VS, et al. Macrophage Migration Inhibitory Factor (MIF): Biological Activities and Relation with Cancer. Pathol Oncol Res 2017;23(2):235–44.
14. Babu SN, Chetal G, Kumar S. Macrophage migration inhibitory factor: a potential marker for cancer diagnosis and therapy. Asian Pac J Cancer Prev 2012;13(5):1737–44.
15. Hudson JD, Shoaibi MA, Maestro R, Carnero A, Hannon GJ, Beach DH. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med 1999;190(10):1375–82.
16. Meyer-Siegler KL, Vera PL, Iczkowski KA, Bifulco C, Lee A, Gregersen PK, et al. Macrophage migration inhibitory factor (MIF) gene polymorphisms are associated with increased prostate cancer incidence. Genes Immun 2007;8(8):646–52.
17. Hira E, Ono T, Dhar DK, El-Assal ON, Hishikawa Y, Yamanoi A, et al. Overexpression of macrophage migration inhibitory factor induces angiogenesis and deteriorates prognosis after radical resection for hepatocellular carcinoma. Cancer 2005;103(3):588–98.
18. Kamimura A, Kamachi M, Nishihira J, Ogura S, Isobe H, Dosaka-Akita H, et al. Intracellular distribution of macrophage migration inhibitory factor predicts the prognosis of patients with adenocarcinoma of the lung. Cancer 2000;89(2):334–41.
19. Lang T, Foote A, Lee JP, Morand EF, Harris J. MIF: Implications in the Pathoetiology of Systemic Lupus Erythematosus. Front Immunol 2015;6:577.
20. Tong X, Zheng B, Tong Q, Liu S, Peng S, Yang X, et al. The MIF -173G/C gene polymorphism increase gastrointestinal cancer and hematological malignancy risk: evidence from a meta-analysis and FPRP test. Int J Clin Exp Med 2015;8(9):15949–57.
21. Vera PL, Meyer-Siegler KL. Association between macrophage migration inhibitory factor promoter region polymorphism (-173 G/C) and cancer: a metaanalysis. BMC Res Notes 2011;4:395.
22. Ramireddy L, Lin CY, Liu SC, Lo WY, Hu RM, Peng YC, et al. Association study between macrophage migration inhibitory factor-173 polymorphism and acute myeloid leukemia in Taiwan. Cell Biochem Biophys 2014;70(2):1159–65.
23. Yuan Q, Wang M, Wang M, Zhang Z, Zhang W. Macrophage migration inhibitory factor gene -173G>C polymorphism and risk of bladder cancer in southeast China: a case-control analysis. Mol Biol Rep 2012;39(3):3109–15.
24. Ding GX, Zhou SQ, Xu Z, Feng NH, Song NH, Wang XJ, et al. The association between MIF-173 G>C polymorphism and prostate cancer in southern Chinese. J Surg Oncol 2009;100(2):106–10.
25. Nabizadeh Marvast M, Sima HR, Ghaffarzadehgan K, Taghizadeh Kermani A, Norouzi N. Clinicopathological significance of macrophage migration inhibitory factor and its relation with p53 in gastric cancer. J Gastrointest Cance. 2011;42(1):5–10.
26. He LJ, Xie D, Hu PJ, Liao YJ, Deng HX, Kung HF, et al. Macrophage migration inhibitory factor as a potential prognostic factor in gastric cancer. World J Gastroenterol. 2015 Sep 14;21(34):9916–26.
27. Li ZW, Wu Y, Sun Y, Liu LY, Tian MM, Feng GS, et al. Inflammatory cytokine gene polymorphisms increase the risk of atrophic gastritis and intestinal metaplasia. World J Gastroenterol 2010;16(14):1788–94.
28. Ramireddy L, Chen WT, Peng CT, Hu RM, Ke TW, Chiang HC, et al. Association Between Genetic Polymorphism of the MIF Gene and Colorectal Cancer in Taiwan. J Clin Lab Anal 2015;29(4):268–4.

APA	pehlivan s, Isiksacan N, PEHLİVAN M, Gunaldi M, Oyacı Y, Nursal A (2020). The MIF rs755622 Variant may Increase Susceptibility of Breast Cancer but not Gastrointestinal Cancer in a Turkish Population. , 283 - 288. 10.5505/tjo.2020.2186
Chicago	pehlivan sacide,Isiksacan Nilgun,PEHLİVAN MUSTAFA,Gunaldi Meral,Oyacı Yasemin,Nursal Ayse Feyda The MIF rs755622 Variant may Increase Susceptibility of Breast Cancer but not Gastrointestinal Cancer in a Turkish Population. (2020): 283 - 288. 10.5505/tjo.2020.2186
MLA	pehlivan sacide,Isiksacan Nilgun,PEHLİVAN MUSTAFA,Gunaldi Meral,Oyacı Yasemin,Nursal Ayse Feyda The MIF rs755622 Variant may Increase Susceptibility of Breast Cancer but not Gastrointestinal Cancer in a Turkish Population. , 2020, ss.283 - 288. 10.5505/tjo.2020.2186
AMA	pehlivan s,Isiksacan N,PEHLİVAN M,Gunaldi M,Oyacı Y,Nursal A The MIF rs755622 Variant may Increase Susceptibility of Breast Cancer but not Gastrointestinal Cancer in a Turkish Population. . 2020; 283 - 288. 10.5505/tjo.2020.2186
Vancouver	pehlivan s,Isiksacan N,PEHLİVAN M,Gunaldi M,Oyacı Y,Nursal A The MIF rs755622 Variant may Increase Susceptibility of Breast Cancer but not Gastrointestinal Cancer in a Turkish Population. . 2020; 283 - 288. 10.5505/tjo.2020.2186
IEEE	pehlivan s,Isiksacan N,PEHLİVAN M,Gunaldi M,Oyacı Y,Nursal A "The MIF rs755622 Variant may Increase Susceptibility of Breast Cancer but not Gastrointestinal Cancer in a Turkish Population." , ss.283 - 288, 2020. 10.5505/tjo.2020.2186
ISNAD	pehlivan, sacide vd. "The MIF rs755622 Variant may Increase Susceptibility of Breast Cancer but not Gastrointestinal Cancer in a Turkish Population". (2020), 283-288. https://doi.org/10.5505/tjo.2020.2186

APA	pehlivan s, Isiksacan N, PEHLİVAN M, Gunaldi M, Oyacı Y, Nursal A (2020). The MIF rs755622 Variant may Increase Susceptibility of Breast Cancer but not Gastrointestinal Cancer in a Turkish Population. Türk Onkoloji Dergisi, 35(3), 283 - 288. 10.5505/tjo.2020.2186
Chicago	pehlivan sacide,Isiksacan Nilgun,PEHLİVAN MUSTAFA,Gunaldi Meral,Oyacı Yasemin,Nursal Ayse Feyda The MIF rs755622 Variant may Increase Susceptibility of Breast Cancer but not Gastrointestinal Cancer in a Turkish Population. Türk Onkoloji Dergisi 35, no.3 (2020): 283 - 288. 10.5505/tjo.2020.2186
MLA	pehlivan sacide,Isiksacan Nilgun,PEHLİVAN MUSTAFA,Gunaldi Meral,Oyacı Yasemin,Nursal Ayse Feyda The MIF rs755622 Variant may Increase Susceptibility of Breast Cancer but not Gastrointestinal Cancer in a Turkish Population. Türk Onkoloji Dergisi, vol.35, no.3, 2020, ss.283 - 288. 10.5505/tjo.2020.2186
AMA	pehlivan s,Isiksacan N,PEHLİVAN M,Gunaldi M,Oyacı Y,Nursal A The MIF rs755622 Variant may Increase Susceptibility of Breast Cancer but not Gastrointestinal Cancer in a Turkish Population. Türk Onkoloji Dergisi. 2020; 35(3): 283 - 288. 10.5505/tjo.2020.2186
Vancouver	pehlivan s,Isiksacan N,PEHLİVAN M,Gunaldi M,Oyacı Y,Nursal A The MIF rs755622 Variant may Increase Susceptibility of Breast Cancer but not Gastrointestinal Cancer in a Turkish Population. Türk Onkoloji Dergisi. 2020; 35(3): 283 - 288. 10.5505/tjo.2020.2186
IEEE	pehlivan s,Isiksacan N,PEHLİVAN M,Gunaldi M,Oyacı Y,Nursal A "The MIF rs755622 Variant may Increase Susceptibility of Breast Cancer but not Gastrointestinal Cancer in a Turkish Population." Türk Onkoloji Dergisi, 35, ss.283 - 288, 2020. 10.5505/tjo.2020.2186
ISNAD	pehlivan, sacide vd. "The MIF rs755622 Variant may Increase Susceptibility of Breast Cancer but not Gastrointestinal Cancer in a Turkish Population". Türk Onkoloji Dergisi 35/3 (2020), 283-288. https://doi.org/10.5505/tjo.2020.2186